Homepage Plandai Biotechnology
Seite 3 von 5 Neuester Beitrag: 18.10.21 15:42 | ||||
| Eröffnet am: | 03.02.14 12:41 | von: Andrew6466 | Anzahl Beiträge: | 106 |
| Neuester Beitrag: | 18.10.21 15:42 | von: pennystockfi. | Leser gesamt: | 22.538 |
| Forum: | Hot-Stocks | Leser heute: | 10 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | | 4 | 5 > | ||||
Plandaí Biotechnology, Inc.
17 Hanover Square
London W1S 1BN
United Kingdom
44 91 7900 9829
http://www.plandaibiotech.com
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 250
Scheint sich aber auszupendeln.
Ich setze auf nächste Woche - und hoffe auf einen Ausbruch Richtung 10 US-Cent,vielleicht
kanpp drüber bis 0,12 US-Cent mal kurz.
Was meint ihr ??
Cannabis Stock Leader: Plandai Biotechnology Inc (OTO:PLPL) Surges 7.32% in Early Trading on October 21
Jeremy Wilchek Market Movers 5 Views
Plandai Biotechnology Inc (OTO:PLPL) came out strong at the opening of trading on October 21, outpacing most other peers in the directory of approximately 200 stocks we track in the cannabis industry with an early advance of 7.32%. After closing the previous session at $0.041, shares of PLPL opened this morning at $0.044 and are currently trading at $0.044. So far, about 81,700 shares have changed hands, compared to an average 30-day volume of 1.92 million for Plandai Biotechnology Inc. Shares moved as high at $0.044 and as low as $0.04 in today’s early action.
The share appreciation gives the company a market capitalization of $7.65 million based upon 186.53 million shares outstanding.
In the past 52 weeks, shares of Plandai Biotechnology Inc have traded as low as $0.0101 and as high as $0.101. Technical traders will take note that at $0.044, shares of PLPL are trading above their 50-day moving average (MA) at $0.021 and below their 200-day MA at below $0.045. Technical analysts pay close attention to these key moving averages because they often serve as technical support and resistance levels and because a move above them is typically regarded as bullish.
Who is $Plandai Biotech?
Plandai Biotechnology Inc, together with its subsidiaries, is engaged in production of proprietary botanical extracts for the nutriceutical and pharmaceutical industries. The company is led by its CEO Roger Duffield from its headquarters in London, .
For more information on Plandai Biotech and other companies focused on the expanding legal cannabis and medical marijuana industries or to considered for contributing content, visit PotNetwork.com today.
All data provided by QuoteMedia and was accurate as of 9:30AM ET.
About PotNetwork.com
PotNetwork.com is a leading publisher of market news, commentary, proprietary research and videos from seasoned journalists, analysts and contributors covering the legal cannabis and medical marijuana markets. Leveraging our extensive distribution network and social media presence, we have cultivated a valuable audience of engaged market enthusiasts interested in all segments, which in turn delivers a variety of unique opportunities for industry partnerships, corporate communications and market exposure. A complete disclaimer can be viewed here.
Wäre schön wenn man mal wieder was postives von PLPL hören würde, der Kurs würde
dann sicherlich nicht mehr bei 4 Cent - sondern vielleicht bei 40 Cent stehen - wenn eine
ähnliche PR wie 2014 kommen würde. ( lest selbst )
x
x
NEW YORK, NY--(Marketwired - Feb 14, 2014) - If Plandaí Biotechnology ( OTCQB : PLPL ) investors liked the idea of Diego Pellicer co-founder Jamen Shively working with the company from the outside, then they'll love the idea that he's now on the inside of this public biotech. Jamen Shively, a former Microsoft executive turned marijuana entrepreneur, has gone public being named to the Board of Directors at Plandaí.
His experience at Microsoft alone makes this a great business move, but the media's attraction to Shively's confident approach to capturing 40 percent of the worldwide marijuana market makes his addition inside any public company a really big deal. Hopefully Plandaí is prepared for the media frenzy that is likely to occur when the national press that showed up en masse to his 2013 press conference, learns of Shively's appointment to the Board.
Plandaí recently completed a deal with Diego Pellicer, Inc. that allows it to market its Phytofare™ Cannabis extracts under the Diego Pellicer Gold brand, so it makes a lot of sense to Roger Duffield, CEO of Plandaí, to have Jamen Shively spearheading that branding process from inside the company. "Jamen brings a wealth of experience in both engineering and branding to Plandaí not to mention his bold leadership in the Cannabis field."
It's that bold leadership that makes Shively so attractive to the media and his "first to mind" approach will keep him in the headlines as the marijuana debate unfolds. With headlines like: "Ex-Microsoft Employee Is Going Big In The Marijuana Business," "Jamen Shively, Former Microsoft Manager, To Launch 'Premium Marijuana' Business In Washington," and "Ex-Microsoftie Jamen Shively Is Building A Marijuana Empire," Shively is clearly proving his point.
The man some are calling the "Bill Gates of Cannabis" has the attention of the media and can likely command a microphone or writer just about any time he wants. For Plandaí and its investors, Shively's not a bad guy to have around your public company, especially in a burgeoning market.
And, this is exactly what Duffield understands as his company looks to move into production and sales of its Cannabis extracts. The CEO said, "As a member of Plandaí's Board, Jamen will be instrumental in helping shape our corporate policy and direction as we move from being a research company into production and sales in the coming months."
About Stock Market Media Group
SMMG is a full service IR firm specializing in Research and Content Development. It offers a platform for corporate stories to unfold through the media with Reports, Interviews and Articles. For more information and to read disclaimers and disclosures: www.stockmarketmediagroup.com.
Aktueller den je.........
x
x
Written by ι Stock Market Media Group Staff — January 30, 2014
When Plandaí Biotechnology (OTCQB: PLPL) entered into an agreement with Diego Pellicer and Diego Pellicer Worldwide to brand its Phytofare™ Cannabis extracts, one has to wonder if the company knew just how big a media platform its new partner has. If you’re an investor in Plandaí, it might be time to get excited about who your company is partnered with. The media and its microphones showed up in large numbers at a Seattle press conference where marijuana entrepreneur and Diego Pellicer co-founder Jamen Shively announced he would be creating the first retail brand of marijuana in the United States.
Shively, a former Microsoft executive, was flanked by the former president of Mexico, Vicente Fox as he presented his plans to capture 40 percent of the worldwide marijuana market and answered a host of questions from the media. In the days, weeks and months following that event, Shively has been interviewed by just about every media publication, and he’s made the rounds on all the network and cable news shows.
The media loves Jamen Shively, and if he has something to say, they’ll provide the platform for him to say it. He’s not alone though. Just yesterday CBS News called on Diego Pellicer’s CEO, Ron Throgmartin, to discuss the industry since Colorado began selling recreational marijuana legally this month.
In the interview, Throgmartin predicted marijuana will be legalized nationwide in as little as two years. “I think by 2016 California will go legal. And, I think once a state the size of California goes, I think, the rest of the country follows.”
One thing is clear, when Plandaí begins to market its Cannabis extracts under the Diego Pellicer brand, the company’s name is likely going to be mentioned again and again on television networks like CBS, CNN, CNBC, FOX, and ABC. It’s the genius in the partnership − because while every other public company awaits legalization, Plandaí will be building its brand!
Und Ende der Woche weiterer Anstieg auf 17 Cent......
(Manchmal darf man auch etwas träumen *g* )
Wünsch uns allen eine tolle "Pot-Woche" mit weiteren Anstiegen bei den Cannabis-Akiten in
USA - so kurz vor dem Abstimmung am 8 Nov.
Wie weit werden wir sehen.
Mit 15 €-Cent bis zum 07.11. wäre ich zufrieden.
wir auch bald Richtung 20-30-40 US-Cent hochschießen......
Was meint ihr ??
Bin echt gespannt - wo dei Fahnenstange hingeht jetzt dann...........
Das innerhalb von glaub ich - in nur ca. 6 Wochen.
Jetzt bei 0,05 Dollar kommt vielleicht die 2. Chance.
Muss nicht auf 3 Dollar gehen - aber vielleicht 1,5 Dollar bis Anfang 2017 ????
Wer weiß das schon.
Es kommt ja auch ein Spinn off einer Beteiligung an die Börse demnächst.
Cannabis Biosciences, Inc - wo 25 % der Aktien an die Börse kommen sollen.
PLPL könnte bald wieder richtig "in" werden in USA - dann wird der Kurs wo anders
stehen als heute bei nur 0,05 US-Dollar !!! A. m. M.
Egal - der Tag wird kommen. Und vielleicht auch ein Kurs - der drüber liegt :-)
Ich meld mich - wenn es bei PLPL wieder los geht - und Schwung reinkommt..........bis denn.
Hoff - und denke auch - nächste Woche wird interessanter - ein Anstieg über das
Zwischenhoch bei ca. 0,065 - wird zu einem Anstieg Richtung 10 Cent führen.
Was dann passiert -..............???.............lassen wir uns überraschen :-)
Schönes WE !!
Nachdem Aktien wie AMMJ super laufen - denke wird auch bald die 2.Reihe der Aktien
aus den Jahren 2013/2014 wiederentdeckt werden.
Nachdem AMMJ schon knapp Faktor 10 x sich verteuert hat, könnte dies
evtl. bei PLPL noch folgen.........10 Cent als ersten Etappenziel - danach 50 Cent ????
Was meint ihr dazu ?? Wer ist bei PLPL noch dabei ??
Vielleicht laufen wir irgendwann nochmal, in der nächsten Zeit, Aktien wie CANN und AMMJ
den Rang ab........rein Kurstechnsich gesehen :-) ???
Wird ne spannende Woche - die nächste - so - so - oder so..... *g*
schießen - ist hier LUFT und Raum locker bis 0,20 - 0,30 Cent....
Was meint ihr ?
sind nach oben ( fast ) keine Grenzen gesetzt.
im Vergleich zum letzten MJ-Aktien Anstieg in 2014.
Auch das zeigt das Potential bei PLPL - zumindest aus Sicht vom Aktienkurs.
